Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy?
Intellia Therapeutics stock soars on promising Phase 3 results for its hereditary angioedema (HAE) candidate. But is there any further upside left in NTLA shares?
Barchart ·